This is the authors' abstract. We don't add key points for this paper.
Objective: To determine ocular changes, particularly in vitreous chamber length (VCL) and corneal volume (CV), analyze globe biometric features in emmetrope pediatric beta-thalassemia major (βTM) patients using Cirrus topography and IOLMaster devices, and compare the results to age- and gender-matched healthy individuals. Material and Methods: This cross-sectional case-control study included 36 multi-transfused β-TM patients (Group 1, 72 eyes) with a mean age of 9.18±3.14 years and no other hemoglobinopathies or anemias unrelated to β-TM. A control group (Group 2, 72 eyes) included 36 healthy children who had routine ophthalmology exams. A comprehensive ophthalmologic exam was performed, including auto-refraction, best-corrected visual acuity, and intraocular pressure (IOP), followed by dilated slit-lamp biomicroscopy. The corneal topography and globe biometric evaluation were followed by a pair-wise data comparison. Results: The axial length (AL) (22.58±0.64 vs 23.06±0.71 mm), VCL (15.48±0.68 vs 15.92±0.69 mm), CV (55.47±2.95 vs 57.65±2.83 mm3), IOP (12.68±2.34 vs 11.08±1.68 mmHg), keratometry values (K1, K2, Kmean, Kapex), as well as central corneal thickness (523.00±28.41 vs 547.29±26.45 μm), were all significantly different between groups 1 and 2, respectively (p0.05). Conclusion: β-TM patients appear to have significant ocular growth retardation than relatively age-matched healthy children, as demonstrated by shorter AL and VCL, as well as lower CV. This circumstance could have prompted compensatory biometric modifications, as evidenced by a relatively steeper cornea and thicker crystalline lens, to accomplish emmetropization.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Gobeka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: